Three Seasons Wealth LLC Acquires New Shares in Pacira BioSciences, Inc. $PCRX

Three Seasons Wealth LLC acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 23,331 shares of the company’s stock, valued at approximately $604,000. Three Seasons Wealth LLC owned approximately 0.05% of Pacira BioSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Hantz Financial Services Inc. boosted its holdings in shares of Pacira BioSciences by 175.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after acquiring an additional 721 shares during the last quarter. Tidemark LLC purchased a new position in shares of Pacira BioSciences during the third quarter valued at approximately $56,000. Strs Ohio bought a new position in Pacira BioSciences during the first quarter valued at approximately $75,000. iSAM Funds UK Ltd bought a new position in Pacira BioSciences during the third quarter valued at approximately $80,000. Finally, Vestcor Inc purchased a new stake in Pacira BioSciences in the third quarter worth approximately $90,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX opened at $22.60 on Wednesday. The stock has a market cap of $915.07 million, a PE ratio of 150.67 and a beta of 0.21. Pacira BioSciences, Inc. has a 1 year low of $18.80 and a 1 year high of $27.64. The firm has a fifty day moving average price of $22.02 and a 200-day moving average price of $23.29. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The firm had revenue of $196.87 million for the quarter, compared to analysts’ expectations of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.91 EPS. Equities analysts anticipate that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Insider Transactions at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,261 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the sale, the insider owned 223,640 shares in the company, valued at approximately $5,103,464.80. This trade represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the sale, the senior vice president directly owned 52,313 shares in the company, valued at $1,088,633.53. This trade represents a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 8,677 shares of company stock worth $191,980. Insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PCRX shares. Barclays cut their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a research note on Friday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and an average price target of $30.25.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.